Search clinical trials for: ARGX-110

Total 6977 results

OncoVerity, Inc.
Janssen Research & Development, LLC; argenx

Completed

A Study of ARGX-110 in Participants With Advanced Malignancies

Neoplasms

France, Belgium
Helios Albert-Schweitzer-Klinik Northeim

Completed

Endocuff-assisted Versus Cap-assisted Versus Standard Colonoscopy (EC-Cap-SC)

Colorectal Polyps | Colorectal Adenomas

Germany, Poland
argenx

Completed

SAD and MAD Study With IV and SC Doses of ARGX-117 (ARGX-117)

Healthy Volunteers

Netherlands
argenx

Completed

A Phase 1b Study of ARGX-111 in Patients With Advanced Cancer.

Cancer

Belgium
argenx

Completed

A Study to Compare the PK, PD and Safety and Tolerability of a SC With an IV Formulation of ARGX-113 in Healthy Male Subjects

Bioavailability Study

Netherlands
argenx

Not yet recruiting

A Safety and Efficacy Study of ARGX-119 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS) (ReALiSe)

Amyotrophic Lateral Sclerosis
argenx

Recruiting

ARGX-117 in Deceased Donor Kidney Transplant Recipients at Risk for Delayed Graft Function (VARVARA)

Delayed Graft Function

Australia, Spain, Belgium, France, Portugal, Canada
argenx

Recruiting

A Clinical Trial to Investigate the Long-term Safety and Tolerability, Efficacy, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of ARGX-117 in Adults With Multifocal Motor Neuropathy (ARDA+)

Multifocal Motor Neuropathy (MMN)

United Kingdom, Spain, United States, Italy, Netherlands, Germany, France, Belgium, Canada, Poland, Austria
argenx

Active, not recruiting

A Clinical Trial to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of 2 Dose Regimens of ARGX-117 in Adults With Multifocal Motor Neuropathy (ARDA)

Multifocal Motor Neuropathy

United States, France, Germany, Belgium, Italy, Netherlands, Canada, United Kingdom, Austria, Poland, Spain
argenx
Quintiles, Inc.

Completed

A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness

Myasthenia Gravis

Italy, United States, Belgium, Canada, Netherlands, Poland, Spain, Sweden
argenx
Quintiles, Inc.

Completed

A Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of ARGX-113 in Patients With ITP

Primary Immune Thrombocytopenia

Austria, Belgium, France, Germany, Spain, Czechia, Hungary, Poland, Ukraine, United Kingdom
argenx

Active, not recruiting

A Long-term Study to Assess the Safety and Efficacy of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP). (ADVANCE+)

Primary Immune Thrombocytopenia

United States, Austria, Belgium, Bulgaria, Czechia, France, Georgia, Germany, Hungary, Italy, Japan, Netherlands, Poland, Russian Federation, Spain, Turkey, United Kingdom, Ukraine
argenx

Withdrawn

A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP) (ADVANCE2)

Primary Immune Thrombocytopenia (ITP)
argenx

Completed

An Efficacy and Safety Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness (ADAPT)

Generalized Myasthenia Gravis

United States, Belgium, Canada, Czechia, Denmark, France, Georgia, Germany, Hungary, Italy, Japan, Netherlands, Poland, Russian Federation, Serbia, United Kingdom
argenx

Recruiting

A Clinical Trial to Investigate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single and Multiple Ascending Doses of ARGX-119 in Healthy Participants

Healthy Volunteers

Netherlands
argenx

Completed

IV Dose Study to Assess the Safety, Tolerability, PK, PD and Immunogenicity of ARGX-113 in Healthy Volunteers

Healthy Volunteers
argenx

Completed

A Safety and Tolerability Study of ARGX-113 in Patients With Myasthenia Gravis Who Have Generalized Muscle Weakness. (ADAPT+)

Generalized Myasthenia Gravis

United States, Belgium, Canada, Czechia, Denmark, France, Georgia, Germany, Hungary, Italy, Japan, Netherlands, Poland, Russian Federation, Serbia
argenx

Approved for marketing

Efgartigimod Expanded Access for Generalized Myasthenia Gravis

Generalized Myasthenia Gravis

United States
argenx

Completed

A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP). (ADVANCE)

Primary Immune Thrombocytopenia

United States, Austria, Belgium, Bulgaria, Czechia, France, Georgia, Germany, Hungary, Italy, Japan, Netherlands, Poland, Russian Federation, Spain, Turkey, Ukraine, United Kingdom
argenx

Completed

A Study of ARGX-110 in Patients With Nasopharyngeal Carcinoma (NPC)

Cancer

Belgium
argenx

Completed

A Study to Evaluate the Safety, PD, PK and Efficacy of ARGX-113 in Patients With Pemphigus

Pemphigus Vulgaris | Pemphigus Foliaceus

Germany, Hungary, Israel, Italy, Ukraine
argenx

Active, not recruiting

A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves) (ADHERE+)

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

United States, Austria, Belgium, Bulgaria, China, Czechia, Denmark, France, Georgia, Germany, Israel, Italy, Japan, Netherlands, Poland, Russian Federation, Serbia, Spain, Ukraine, United Kingdom, Latvia, Romania, Taiwan, Turkey
OncoVerity, Inc.
Janssen Research & Development, LLC; argenx

Completed

A Study of ARGX-110 in Combination With Azacytidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) or High Risk Myelodysplatic Syndrome (MDS)

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

Switzerland, France
argenx

Completed

Efgartigimod Co-administered Subcutaneously With rHuPH20 in Healthy Subjects

Healthy Volunteers

Netherlands
Yonsei University

Completed

Lower Femtosecond Laser Energy Levels Lead to Better Visual Recovery After Small-incision Lenticule Extraction for Myopia

Myopia

Korea, Republic of
argenx

Recruiting

A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia (ADVANCE SC+)

Primary Immune Thrombocytopenia

United States, Australia, Bulgaria, China, Georgia, Greece, Italy, Japan, Poland, Portugal, Romania, Russian Federation, Thailand, Turkey, Argentina, Chile, Ireland, Jordan, Tunisia, Korea, Republic of, Mexico, New Zealand, South Africa and more
argenx

Not yet recruiting

A Phase 1b Study to Investigate Safety and Tolerability of ARGX-119 in Adult Participants With DOK7-Congenital Myasthenic Syndromes (CMS)

Congenital Myasthenic Syndrome
argenx

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia (ADVANCE SC)

Primary Immune Thrombocytopenia

United States, France, Georgia, Germany, Italy, Japan, Poland, Russian Federation, Spain, Turkey, United Kingdom, Argentina, Australia, Bulgaria, Chile, China, Denmark, Greece, Ireland, Israel, Jordan, Korea, Republic of, Mexico, New... and more
REGENXBIO Inc.

Active, not recruiting

RGX-111 Gene Therapy in Patients With MPS I

Hurler Syndrome | Hurler-Scheie Syndrome | Mucopolysaccharidosis Type I (MPS I)

United States, Brazil, Israel
argenx

Not yet recruiting

A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis (empacific)

Myositis | Dermatomyositis
Johnson & Johnson Vision Care, Inc.

Completed

Evaluating Soft Contact Lens Prototypes for Myopia Control

Visual Acuity

China
Janssen Research & Development, LLC
argenx

Withdrawn

A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT)

Myelodysplastic Syndromes | Leukemia, Myelomonocytic, Chronic

United Kingdom, Switzerland, Italy, Germany, France, Spain, Australia, Turkey, Brazil, Russian Federation, Saudi Arabia
MetiMedi Pharmaceuticals

Unknown

OMT-111 for Terminal Stage Solid Tumors

Breast Cancer | Pancreatic Cancer | Lung Cancer

Vietnam
OncoVerity, Inc.
Janssen Pharmaceutical K.K.; argenx

Completed

A Study of Cusatuzumab Plus Azacitidine in Japanese Participants With Newly Diagnosed Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Who Are Not Candidates for Intensive Treatment

Leukemia, Myeloid, Acute

Japan
OncoVerity, Inc.
Janssen Research & Development, LLC; argenx

Active, not recruiting

Cusatuzumab in Combination With Background Therapy for the Treatment of Participants With Acute Myeloid Leukemia (ELEVATE)

Leukemia, Myeloid, Acute

Canada, United States, Poland, Switzerland, Germany
Heat Biologics

Completed

A Phase 1 Study of HS130 in Combination With Viagenpumatucel-L (HS110) in Patients With Solid Tumors

Advanced Solid Tumor

United States
Clinical Nutrition Research Centre, Singapore

Completed

The Lunch Study: the Combined Effects of Food Texture and Portion Size on Intake

Satiation

Singapore
PegBio Co., Ltd.
Covance

Completed

Dose-finding of PB-119 Administered Subcutaneously Once Weekly Versus Placebo in Subjects With Type 2 Diabetes

Type 2 Diabetes Mellitus (T2DM)

United States
Hospital General Universitario Elche

Unknown

RYGB AL 150cm BPL 100cm vs RYGB AL 100cc BPL 150cm

Weight Loss
TR Therapeutics

Completed

Efficacy Study of GLYC-101 to Evaluate Outcomes After Laser Ablation

Wounds

United States
National Cancer Institute (NCI)

Terminated

Mesothelin-Targeted Immunotoxin LMB-100 in Combination With SEL-110 in Subjects With Malignant Pleural or Peritoneal Mesothelioma

Mesothelioma

United States
TR Therapeutics

Completed

Efficacy Study of GLYC-101 to Evaluate Outcomes After Post-laser Ablation

Wounds

United States
Nocion Therapeutics

Completed

Placebo-controlled, Single and Multiple Dose Study in Healthy Volunteers and Refractory Chronic Cough Patients to Assess the Safety, Tolerability, and Pharmacokinetics of Two Formulations of NTX-1175

Refractory Chronic Cough

United States
Transposon Therapeutics, Inc.

Active, not recruiting

A Phase 2a Study of TPN-101 in Patients With Progressive Supranuclear Palsy (PSP)

Progressive Supranuclear Palsy

United States
Wake Forest University Health Sciences
Medtronic

Recruiting

Esophagogastric Junction Distensibility During Hiatal Hernia Repair

Hiatal Hernia | Esophagogastric Junction Distensibility

United States
Cancer Trials Ireland

Completed

Spinal Cord Compression Re-Treat Study

Pain | Unspecified Adult Solid Tumor, Protocol Specific | Radiation Toxicity | Spinal Cord Compression

Ireland
Aeglea Biotherapeutics

Completed

A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With Advanced Solid Tumors

Advanced Cancers

United States
AEterna Zentaris

Completed

Investigation of a New, Oral Growth Hormone Secretagogue, AEZS-130 as a Growth Hormone Stimulation Test.

Diagnosis of Adult Growth Hormone Deficiency (AGDH)

United States
AbbVie
AbbVie

Recruiting

RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) Without Center Involved-Diabetic Macular Edema (CI-DME) (ALTITUDE)

Diabetic Retinopathy (DR)

United States
PhotonMD, Inc

Completed

Modulated Light Therapy in Participants With Pattern Hair Loss

Androgenetic Alopecia

Australia

Search clinical trials for: ARGX-110

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kyrgyzstan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations